James Glencross

USPTO Granted Patents = 29 (Patent Applications = 2)

CIPO Patents = 8 (Patent Applications = 4)

EPO Patents = 8 (Patent Applications = 15)

Average Co-Inventor Count = 5.3

ph-index = 10

Forward Citations = 597(Granted Patents)

Location History:

Musselburgh, GB (2023)
Edinburgh, GB (2012 - 2024)

Company Filing History:

7 out of 2,078

Janssen Pharmaceutica Nv

patents

6 out of 410

Janssen Biotech, Inc.

Janssen Pharmaceuticals, Inc.

patents

6. 2 out of 119

Lifescan Scotland Limited

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. D1086441 - Intranasal drug delivery device (2025-07-29),

2. 12008916 - Devices and methods for drug administration and mixing, and training of proper techniques therefor (2024-06-11),

3. D1007675 - Pharmaceutical ingredient mixing training device (2023-12-12),

4. 11724035 - Injection device with ergonomic housing form factor (2023-08-15),

5. 11657731 - Devices and methods for drug administration and mixing, and training of proper techniques therefor (2023-05-23),

6. 11633546 - Palm activated drug delivery device (2023-04-25),

7. 11574562 - Devices and methods for drug administration and mixing, and training of proper techniques therefor (2023-02-07),

8. 11450235 - Devices and methods for drug administration and mixing, and training of proper techniques therefor (2022-09-20),

9. D956215 - Autoinjector (2022-06-28),

10. D946141 - Autoinjector (2022-03-15),

11. 11037465 - Devices and methods for drug administration and mixing, and training of proper techniques therefor (2021-06-15),

12. 10861351 - Devices and methods for drug administration and mixing, and training of proper techniques therefor (2020-12-08),

13. 10485931 - Palm activated drug delivery device (2019-11-26),

14. D854954 - Wireless sensor without display and with magnet (2019-07-30),

15. D854953 - Wireless sensor with display and with boot (2019-07-30),

Title: The Innovative Contributions of James Glencross

Introduction

James Glencross, an accomplished inventor based in Edinburgh, GB, has made significant strides in the field of pharmaceutical technology. With 28 patents to his name, his work focuses on advancing drug administration techniques and enhancing the mixing of pharmaceutical components. His inventive spirit and dedication to innovation have established him as a prominent figure in his industry.

Latest Patents

Among his latest patents, Glencross has developed devices and methods for drug administration and mixing, as well as training users on proper techniques. One notable invention is a training device designed to instruct users in the appropriate mixing of pharmaceutical components. This device features a housing for a pharmaceutical delivery device and incorporates a microcontroller alongside a motion and orientation detection device, all working in cohesive communication. This inventive approach not only aids in the mixing process but also ensures accurate and effective administration of pharmaceutical components.

Career Highlights

Throughout his career, Glencross has collaborated with esteemed organizations such as Janssen Biotech, Inc. and Aktiebolaget SKF. His contributions have consistently focused on enhancing pharmaceutical practices, demonstrating his ability to marry technology and healthcare effectively.

Collaborations

James has had the pleasure of working with notable colleagues, including Peter A. Krulevitch and Nick Foley. These collaborations have influenced his innovative journey, fostering the exchange of ideas and solutions within the pharmaceutical field.

Conclusion

In conclusion, James Glencross's dedication to innovation within the pharmaceutical industry is exemplified by his extensive number of patents and collaborative efforts. As he continues to develop new solutions for drug administration and mixing, his impact on healthcare technology remains profound and forward-thinking. With each invention, Glencross reinforces the importance of innovation in improving patient care and pharmaceutical practices.

This text is generated by artificial intelligence and may not be accurate.